Omeros CorporationOMERNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Omeros Announces First Commercial Sales of YARTEMLEA®

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpati.

defenseworld.net

David Borges Sells 30,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ: OMER - Get Free Report) CAO David Borges sold 30,000 shares of the company's stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the SEC, which is available at this

defenseworld.net

Omeros (NASDAQ:OMER) Trading Down 5.8% After Insider Selling

Omeros Corporation (NASDAQ: OMER - Get Free Report) shares dropped 5.8% on Thursday following insider selling activity. The stock traded as low as $12.42 and last traded at $12.3160. Approximately 244,474 shares traded hands during trading, a decline of 93% from the average daily volume of 3,314,114 shares. The stock had previously closed at $13.08. Specifically,

defenseworld.net

Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus

Omeros (NASDAQ: OMER) outlined its U.S. launch plans for Yarcomlia (narsoplimab) and discussed clinical data, reimbursement preparations, and supply expectations following the drug's FDA approval on December 23, 2025, during a company conference call led by Chairman and CEO Dr. Gregory Demopulos. FDA approval and scope of the indication Demopulos said Yarcomlia is the first and

seekingalpha.com

Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript

reuters.com

Omeros prices transplant complication drug at $36,000 per dose

Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a call with analysts on Wednesday.

defenseworld.net

Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages

Omeros Corporation (NASDAQ: OMER - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has

zacks.com

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

businesswire.com

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7,.

defenseworld.net

Omeros (NASDAQ:OMER) Hits New 12-Month High – Time to Buy?

Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) hit a new 52-week high on Thursday. The stock traded as high as $17.65 and last traded at $15.0850, with a volume of 24509175 shares traded. The stock had previously closed at $8.75. Key Stores Impacting Omeros Here are the key news stories impacting Omeros

defenseworld.net

Traders Purchase Large Volume of Call Options on Omeros (NASDAQ:OMER)

Omeros Corporation (NASDAQ: OMER - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 29,728 call options on the company. This is an increase of 579% compared to the typical volume of 4,378 call options. Analysts Set New Price Targets OMER has been the subject of a number

fool.com

Why Omeros Stock Skyrocketed Today

It won approval for a medicine that treats a potentially fatal complication from stem cell transplants. This is the first drug approved for that indication.

seekingalpha.com

Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely

Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation. Yartemlea is the first and only approved therapy for TA-TMA, showing high complete response rates and strong survival benefits in pivotal trials. I estimate Yartemlea's peak revenue potential at ~$300m, with commercialization pacing dependent on awareness, funding, and OMER's ability to scale.

benzinga.com

Gold Edges Lower; Omeros Shares Jump

U.S. stocks traded higher midway through trading, with the Dow Jones index surging more than 200 points on Wednesday.

feeds.benzinga.com

FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The FDA has approved Omeros Corporation's Yartemlea for TA-TMA, a fatal complication of stem-cell transplantation, with a 61% success rate.

reuters.com

US FDA approves Omeros' drug to treat dangerous transplant complication

The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.

businesswire.com

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef.

defenseworld.net

Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one

businesswire.com

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in.

seekingalpha.com

Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript

Omeros Corporation ( OMER ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Gregory Demopulos - Co-Founder, Chairman, CEO & President David Borges - VP of Finance, Chief Accounting Officer & Treasurer Nadia Dac - VP & Chief Commercial Officer Conference Call Participants Jennifer Williams Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Stephen Brozak - WBB Securities, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance